Omnicell Q3 profit rises on connected device demand

Overview

• Healthcare technology firm's Q3 revenue declined 1% yr/yr to $308 mln

• Q3 adjusted net income and adjusted EBITDA rose yr/yr

• Company raised full-year 2026 non-GAAP EBITDA and EPS guidance

Outlook

• Omnicell raises full-year 2026 non-GAAP EBITDA guidance to $187 mln-$193 mln

• Company lifts full-year 2026 non-GAAP EPS outlook to $2.48-$2.56

• Omnicell tightens full-year 2026 revenue guidance to $1.225 bln-$1.231 bln

Result Drivers

• CONNECTED DEVICE DEMAND - Co said Q3 results were supported by demand for its connected device portfolio

• PRODUCT AND SERVICE MARGINS - Co attributed Q3 performance to favorable product and service margins

• COST MANAGEMENT - Co cited disciplined cost management as a driver of Q3 results

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Omnicell Inc is $60.00, about 66.9% above its October 28 closing price of $35.95

• The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 20 three months ago

Reuters Recommended Reads

• Oct 28 - GE Healthcare Q3 profit beats estimates on advanced imaging segment

• Oct 28 - Boston Scientific Q3 revenue beats estimates despite cybersecurity disruption

• Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)